RC intervention significantly reversed AMPK/SIRT1/NF-κB activation, thereby decreasing NAFLD fatty acid β oxidation, oxidative stress, and inflammation. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.